Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study

NCT01348880 | Completed Phase 1 DMC

• 1 other identifier: 15345
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 2

Brief Summary

The study will be conducted as a multi-center, randomized, double-blinded, placebo controlled, crossover design. The investigational drug (vardenafil ODT (Orally Disintegrating Tablet)/placebo) will be given as a single administration at a dose of 10 mg vardenafil ODT during Period 1 or 2; the blinded matching placebo will be given as a single administration during the opposing period. The random code will determine the order of active drug (vardenafil ODT) and placebo for each subject. Blood pressure and heart rate profiles will be recorded by automated device pre-dose for 8 hours post-dose during Periods 1 and 2. The non investigational drug product (vasodilator), Procardia XL, will be background treatment for hypertension, taken daily by each subject. All subjects must be stable on the vasodilator for at least 4 weeks prior to Day 1 of Period 1. Special conditions for this study include the requirement that all subjects will be male, are between the ages of 65 and 80 years, and will have a diagnosis of erectile dysfunction (ED), as well as hypertension. Planned sample size will be 40 subjects evaluable for the primary analysis. Of the 40 subjects valid for this analysis, 20 will be between the ages of 65 and 69 years, and 20 subjects will be between the ages of 70 and 80 years. The total duration of the study will be approximately one year from first subject treated to last subject treated, including replacement of any subjects who fail to complete both periods of crossover dosing.

Conditions

Erectile Dysfunction

Keywords

drug-drug interaction

Outcome Measures

Primary Outcomes (1)

• The primary pharmacodynamic variable (endpoint) is the placebo-corrected mean maximal decrease in supine systolic blood pressure from baseline (1 hour before dose) to within 8 hours of dosing with 10 mg ODT formulation of vardenafil HCl and nifedipine.

  Up to 8 hours of combination dosing of vardenafil ODT and nifedipine.

Secondary Outcomes (8)

• Mean maximal decrease in standing SBP

  Up to 8 hours of combination dosing of vardenafil ODT and nifedipine

• Mean maximal decrease in standing diastolic blood pressure (DBP)

  Up to 8 hours of combination dosing of vardenafil ODT and nifedipine

• Mean maximal decrease in supine DBP

  Up to 8 hours of combination dosing of vardenafil ODT and nifedipine

• Mean maximal orthostatic change in SBP (the supine SBP minus the standing SBP)

  Up to 8 hours of combination dosing of vardenafil ODT and nifedipine

• Mean maximal increase in supine and standing heart rate

  Up to 8 hours of combination dosing of vardenafil ODT and nifedipine

Study Arms (2)

Arm1

EXPERIMENTAL

Drug: Vardenafil ODT, (Staxyn, BAY38-9456)

Arm2

PLACEBO COMPARATOR

Drug: Placebo

Interventions

Vardenafil ODT, (Staxyn, BAY38-9456) DRUG

Single dose of 10 mg of vardenafil ODT, taken without water

Arm1

Placebo DRUG

Single dose of placebo to match 10 mg vardenafil ODT. taken without water

Arm2

Eligibility Criteria

• Age: 65 Years - 80 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Subjects must fulfill all of the following criteria before being included in the treatment period i.e., before receiving any dose of the study related medication (Sponsor supplied Procardia XL, or vardenafil Orally Disintegrating Tablet (ODT) /placebo tablets):
• The informed consent must be signed before any study specific tests or procedures are done
• Male gender
• Diagnosis of both essential hypertension (HTN) and erectile dysfunction (ED)
• High blood pressure, or hypertension, is defined in an adult as a systolic pressure of 140 mm Hg or higher and/or a diastolic pressure of 90 mm Hg or higher. As stated in the current American Heart Association guidelines.
• Documented ED for more than 6 months according to the National Institutes of Health (NIH) Consensus statement (the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). The diagnosis for ED will be confirmed using the five-item version (Rosen RC) of the International Index of Erectile Function (IIEF-5), see Appendix 14.4. The total IIEF-5 score must be at least 8, and not exceed 19. Subjects must have used at least one Phosphodiesterase-5 (PDE-5) inhibitor, such as Viagra, Levitra or Cialis at some time prior to entry in this study.
• Age: 65 to 80 years (inclusive) at the first screening examination / visit
• Body mass index (BMI): above/equal 18 and below/equal 32 kg / m²

You may not qualify if:

• Subjects are to be excluded from the study if they display any of the following criteria:
• Medical and surgical history
• Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal. This includes severe renal impairment (on dialysis or not) and moderate or severe hepatic disease.
• Known hypersensitivity to calcium channel blockers (active substances or excipients of the tablet preparations)
• Known hypersensitivity to PDE-5 inhibitors, such as Viagra, Levitra or Cialis (active substances or in some instances, excipients of the tablet preparations should be considered as possible allergens, e.g., lactose, aspartame)
• Known severe allergies, non-allergic drug reactions, or multiple drug allergies
• Recent history (within 6 months) of myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), stenting, or cerebrovascular accident (CVA)
• Known left ventricular outflow syndrome (LVO)
• History of significant coronary artery disease, e.g., angina
• Congenital or acquired prolonged QT syndrome
• Congestive heart failure (CHF) \[NYHA Class 3 or 4\]
• History of adult epilepsy or other seizure disorders
• History of retinitis pigmentosa
• Use of any anti-hypertensive medication other than the calcium channel blocker, Procardia XL (nifedipine), supplied by the sponsor, during the study
• Any drug known to induce cytochrome P450 (CYP) enzymes (eg rifampicin, carbamazepine, phenytoin, bosentan, dexamethasone, barbiturates, St. John's Wort \[hypericum perforatum\])

Sponsors & Collaborators

• Bayer: lead
• GlaxoSmithKline: collaborator
• Merck Sharp & Dohme LLC: collaborator

Study Sites (2)

Unknown Facility

Miami, Florida, 33014, United States

Location

Unknown Facility

Knoxville, Tennessee, 37920, United States

Location

MeSH Terms

Conditions

Erectile Dysfunction

Interventions

Vardenafil Dihydrochloride

Condition Hierarchy (Ancestors)

Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Sexual Dysfunction, Physiological; Male Urogenital Diseases; Sexual Dysfunctions, Psychological; Mental Disorders

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Piperazines

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2011
• First Posted: May 6, 2011
• Study Start: May 1, 2011
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: May 19, 2014

Record last verified: 2014-05

Locations

US (2)